
June 21 (Reuters) - Gan & Lee Pharmaceuticals 603087.SS:
GAN & LEE PHARMACEUTICALS PRESENTED MULTIPLE RESULTS IN NOVEL DIABETES THERAPIES AT THE AMERICAN DIABETES ASSOCIATION'S 85TH SCIENTIFIC SESSIONS
GAN & LEE PHARMACEUTICALS - PHASE 2A TRIAL SHOWS BOFANGLUTIDE INJECTION REDUCES HBA1C IN T2DM PATIENTS
GAN & LEE PHARMACEUTICALS - PHASE 2B TRIAL SHOWS BOFANGLUTIDE SUPERIOR TO SEMAGLUTIDE IN HBA1C REDUCTION
GAN & LEE PHARMACEUTICALS - PHASE 2 TRIAL SHOWS GZR4 INJECTION SUPERIOR TO TRESIBA IN HBA1C REDUCTION